Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GARDP
Geneva, Switzerlandgardp.org ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
GARDP is developing and facilitating access to new antibiotic treatments for drug-resistant infections, with clinical programs and partnerships across multiple continents. It aims to develop five new treatments by 2025, focusing on serious bacterial infections, neonatal sepsis, and STIs. Landmark licensing with Shionogi on cefiderocol is enabling unprecedented access in low- and middle-income countries.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Academic Hospital/University/Research
02
Partnerships
World Health Organization (WHO)Drugs for Neglected Diseases initiative (DNDi)ShionogiClinton Health Access Initiative (CHAI)
Beyond the preview
Go deeper on GARDP.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GARDP.